N. prodotti: 0
Totale ordine: € 0,00
Online ISSN 1827-174X
Alessandra LUCCHESE 1, 2 , Giovanni MATARESE 3, Maurizio MANUELLI 1, 2, Claudio CIUFFREDA 1, 2, Luca BASSANI 1, 2, Gaetano ISOLA 3, 4, Giancarlo CORDASCO 3, Enrico GHERLONE 1, 2
1 Researcher in Dentofacial Orthopedics, Orthodontics and Pediatric Dentistry, Oral Pathology and Implantology, IRCCS, San Raffaele Hospital, Milan, Italy; 2 Department of Orthodontics, Unit of Dentistry, Vita Salute San Raffaele University, Milan, Italy; 3 Department of Specialist Medical-Surgical Experimental Sciences and Odontostomatology, Policlinic “G. Martino”, University of Messina, Messina, Italy; 4 Department of Neurosciences, Reproductive and Odontostomatological Sciences, School of Medicine, University Federico II of Naples, Naples, Italy
BACKGROUND: Myeloablative and hematopoietic stem cells transplantation therapy (HSCT) often acts as side-effect to oral mucositis (OM) with no effective treatment. This randomized-controlled trial analyzed the efficacy of palifermin, administered as a dose during HSCT therapy, as primary prophylaxis on pediatric patients with acute lymphoblastic leukemia (ALL).
METHODS: In this study forty-six patients (9-15 years) with B-cell acute lymphoblastic leukemia (B-ALL) were analyzed. The patients underwent allogenic HSCT conditioned by myeloablative regimen. Subsequently to randomization, patients in the palifermin group were assigned to receive palifermin, 60 mg/kg, intravenously as a single dose 3 days before and after transplant conditioning regimen cycle. The patients in the Control group received only a placebo treatment. Maximum severity of OM, incidence and duration of ulcerative OM, incidence and duration of severe OM limitations were evaluated.
RESULTS: A statistically significant reduction in the incidence of OM up to grade 3 in the palifermin group compared to the control group was discovered. There was also a reduction, confirmed at 60 days, in the degree of severity of mucositis in the palifermin group, with an average of 1.54 grade in the palifermin group, and of 2.16 in the Control group and in the use of opioid analgesics.
CONCLUSIONS: This study indicates that a single dose of palifermin used as primary prophylaxis during HSTC therapy can prevent severe OM in pediatric patients with ALL and used as secondary prophylaxis can prevent the recurrence of severe OM in high-risk patients with previous mucosal injury and improves the quality of life in pediatric patients with ALL.